The balance between the risk of early stroke recurrence and hemorrhagic transformation represents the cornerstone of practical management of non-valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS). Patients who receive antithrombotic therapy as secondary prevention in the early phase of NVAF-related AIS have a better prognosis compared with patients who do not receive antithrombotic treatment. Recently, the RAF study showed that the best efficacy/safety profile was associated with anticoagulation started between 4 and 14 days from stroke onset. Based on the RAF study, the 2018 American Heart Association/American Stroke Association (AHA/ASA) guidelines suggest starting anticoagulants between 4 and 14 days from stroke onset with a class of recommendation IIa. Strong evidence for the use of direct oral anticoagulants (DOACs) in the early phase of NVAF-related AIS is lacking, because this kind of patients were excluded from phase III randomized clinical trials (RCT) and ad hoc RCTs are ongoing. However, the real life evidence suggests that early starting time of DOACs in patients with NVAF-related AIS is safe and associated with low recurrence risk and all-cause mortality. In the present review the Authors provide an update on anticoagulation in the early phase of NVAF-related AIS with focus on DOACs.
Introduction
Non-valvular atrial fibrillation (NVAF)-related acute ischemic strokes (AIS) represent about one fourth of overall strokes and the most feared stroke subtype due to higher mortality and morbidity risk and more severe functional sequelae compared to other subtypes. 1 Preventing stroke recurrences avoiding hemorrhagic transformation (HT) represents the cornerstone of secondary prevention in NVAF-related AIS. In the absence of secondary pharmacological prevention, the risk of early embolic stroke recurrence is about 1% per day in the first two weeks. 2 HT represents the most feared complication in patients with AIS. Cardioembolic stroke represents one of the main risk factors for HT together with systemic thrombolysis, large vessel stroke etiology, large size infarcts and diabetes. 3 The risk of HT in patients with cardioembolic stroke is three-five folds increased. 3 The incidence of HT in patients with cardioembolic stroke is about 7-10% in the first two weeks from stroke onset. In the VISTA registry 80% of stroke recurrence and HT occurred within day 2 after stroke events. 4 Both stroke recurrence and symptomatic HT are associated with poor prognosis in terms of morbidity, mortality, increased length of hospital stay (LOS) and neurological sequelae. 2, 3, 5, 6 Of note, the occurrence of HT is associated with delay of starting anticoagulation after stroke onset. 6 Table 1 summarizes the classification of HT.
Oral anticoagulants represent the first therapeutic choice for secondary stroke prevention in atrial fibrillation (SPAF). 7 A meta-analysis showed that, in patients with history of stroke, the number needed to treat (NNT) for preventing one stroke by using warfarin was 14 versus placebo and 24 versus antiplatelets. Anticoagulation and acute stroke patients who do not receive antithrombotic treatment. 4 In the VISTA registry the incidence of stroke recurrence, symptomatic intracranial bleeding, all-cause mortality and 90-day modified Rankin scale (mRS) ≥4 in patients with NVAF-related AIS not receiving antithrombotic treatment was 19.8%, 9.3%, 40.7% and 65.3%, respectively compared with patients receiving vitamin K antagonists (VKAs) (10.6%, 2.9%, 25.5% and 46.6%, respectively) or VKAs plus antiplatelets (6.7%, 1.9%, 17.8% and 54.5%, respectively). 4 Baseline median National Institute of Health Stroke scale (NIHSS) score ranged from 16 in patients not receiving antithrombotics to 14 in patients receiving anticoagulants plus antiplatelets. 4 The median starting time of anticoagulants in the VISTA registry was 2 days (interquartile range, 1-4). 4 Despite the prognostic advantages, the optimal timing for starting anticoagulants in the acute phase of NVAF-related AIS remains a clinical dilemma. In patients receiving systemic thrombolysis none additional antithrombotic therapy is indicated in the first 24 h. 7 Aspirin started after 24 h in patients receiving systemic thrombolysis or as soon as possible in patients not receiving systemic thrombolysis is the most appropriate secondary prevention in the first 48 h from stroke onset, whereas anticoagulation in this temporal window is unfavorable for the highest risk of HT. 7, 9 Recently, the RAF study showed that starting anticoagulation with VKAs [i.e. reaching international normalized ratio (INR) ≥2.0] in AIS was associated with a 90-days incidence of transient ischemic attack (TIA)/stroke recurrence or systemic embolism of 6.4% (10.6% in patients non receiving antithrombotic therapy, P=0.023) and hemorrhagic events of 5.4% (3.8% in patients non receiving antithrombotic therapy, P=0.31) and the best efficacy/safety profile was with a start time between 4 and 14 days. The mean time for reaching INR ≥2 was 12.1±15.8 days. 2 In the RAF study the mean baseline NIHSS score was 9.2±7.3. About one fourth (27.1%) of patients had large infarct size. 10 Definition of infarct size in the RAF study is summarized in Table  2 and examples of infarct size in Figure 1 . Based on the RAF study, the latest (2018) American Heart Association/American Stroke Association (AHA/ASA) guidelines suggest to start anticoagulants between 4 and 14 days from stroke onset with a class of recommendation IIa. 7 This temporal window seems wide in the clinical context, and in the single patient the decision on when anticoagulants should be started, if closer to the fourth or fourteenth day, is difficult and at the same time fundamental. The analysis of subgroups of the RAF study showed that CHA 2 DS 2 -VASC score, NIHSS score, size of brain ischemic lesions and left atrial size each independently, could help in the appropriate timing for starting VKAs. 10, 11 Direct oral anticoagulants in the secondary prevention of stroke Evidence for the use of direct oral anticoagulants (DOACs) in the acute phase of NVAF-related AIS is lacking, because this kind of patients were excluded from the phase III randomized clinical trials (RCTs) on DOACs in SPAF. 12, 13 Exclusion criteria related to AIS in phase III RCTs are summarized in Table 3 . However about 14,000 patients enrolled in phase III RCTs on DOACs in SPAF had suffered from a previous TIA/stroke (Table 4) . A post-hoc analysis of phase III RCTs comparing DOACs versus warfarin in SPAF showed a good efficacy/safety profile of DOACs in patients with history of previous TIA/stroke. Compared to warfarin, absolute risk reduction (ARR), relative risk Review reduction (RRR) and NNT were 0.78%, 13.7% and 127, respectively, for preventing stroke or systemic embolism, while ARR, RRR and NNT were 0.88%, 46% and 113, respectively, for preventing intracranial bleeding.
14 Despite the absence of strong literature evidence, DOACs seem to represent a great opportunity in patients with NVAF-related AIS, due to their favorable pharmacological and safety profiles. Based on Expert opinion, guidelines suggest starting DOACs immediately in patients with NVAF-related TIA, after ≥3, 6-8 and 12-14 days in mild (NIHSS score <8), moderate (NIHSS 8-16) or severe (NIHSS score >16 stroke).
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II clinical trials
The TRIPLE-Axel was a phase II RCT comparing low dose rivaroxaban (10 mg) for five days followed by full dose (20 mg, or 15 mg in patients with creatinine clearance 30-49 mL/min) versus warfarin with a target INR of 2.0-3.0 for four weeks in 183 patients with mild (NIHSS ≤4) NVAF-related AIS. This trial showed no difference between the two arms Anticoagulation and acute stroke in the primary composite endpoint of stroke recurrence and/or new intracranial bleeding. 16 Patients receiving rivaroxaban showed a significant shorter LOS (4.0 vs 6.0 days, P<0.001). 16 
Phase III and phase IV clinical trials
Until now, phase III and phase IV clinical trials aimed to analyze efficacy and safety of DOACs in the early phase of NVAF-related AIS are ongoing and results have not been published yet. Table 5 summarizes the design of planned clinical trials in this context.
Real life evidence
In the last years a lot of literature evidence about the introduction of DOACs in the early phase of NVAFrelated AIS was available. More recently, Masotti et al. provided a summary of this literature evidence. 17 The Authors analyzed Pubmed database searching for published articles until June 2018 reporting data on 90-day prognosis of patients receiving DOACs in the first two weeks after NVAF-related AIS. They built their search by combining the terms oral anticoagulants, stroke, acute, early by using the Boolean operators AND/OR. The search was restricted to English language articles, adults (≥18 years), words in title/abstract. Finally, the search strategy was refined by reviewing the bibliography of retrieved articles. Only studies including DOACs and reporting endpoints, such as 90-day TIA/stroke recurrence, HT or intracranial bleeding and all-cause mortality were considered for the analysis. The Authors identified eight studies [18] [19] [20] [21] [22] [23] [24] [25] satisfying the criteria of their search, with different methodology (five prospective observational, two retrospective and one prospective, open label, single arm design). Overall, the eight studies included 2187 patients (49.3% females) of whom 830 were treated with rivaroxaban, 729 with dabigatran, 475 with apixaban and 6 with edoxaban. For 147 data on the type of DOAC used were not available. In all the studies mean or median age of patients was over 70 years. About one third of patients were treated with urgent reperfusion therapy, and about one fifth of patients had large infarct size. Median or mean NIHSS ranged from 2 to 8 points. Median time of starting DOACs ranged from 2 to 8 days, and in seven out of eight selected studies, median or mean starting time was ≤5 days. About 42% of patients received low dose of DOACs.
Ninety-day TIA/stroke recurrence, HT/intracranial bleeding and all-cause mortality occurred in 2.3%, 0.93% and 1.5% of patients, respectively. The Authors concluded that, awaiting results of phase III RCTs, the findings of their overview could open a new scenario, supporting the use of DOACs as the possible treatment of choice in the early phase of NVAF-related AIS, and highlighting that 90-day prognostic outcomes were lower than those reported in the previous studies (Table 6) . 4, 17 However, the Authors, recognized that their review had limitations. In fact, the interpretation of their results should take into account that the selected studies had different designs, none of them had a comparison group, the average stroke severity was mild (median or mean NIHSS at hospital admission is ≤8), about 40% of patients were treated with low doses of DOACs, even if the reason of dose reduction was almost never reported and finally, the follow-up was limited to 90 days.
Recently, data on the 2-year follow-up of the SAMURAI-NVAF registry, examining the long-term risk-benefit profile among patients receiving warfarin Anticoagulation and acute stroke or DOACs, were published: estimated cumulative incidences of stroke and systemic embolism within 2 years were similar between warfarin and DOACs users, but deaths and intracranial hemorrhages were significantly lower among the latter. 26 
Implications for clinical practice
The decision on the optimal time for starting anticoagulants in the acute phase of NVAF-related AIS remains a challenge. Before DOACs era the introduction of anticoagulation in the early phase of NVAF-related AIS was strongly underused. In a previous multicenter study performed in Tuscany at the beginning of this decade (2011), only about one fourth of patients with NVAF-related AIS received VKAs before hospital discharge. More than one half of patients were discharged on antiplatelet therapy. 5 Defining the risk of stroke recurrence and HT is of fundamental importance for anticoagulation starting time. Combining patients of RAF and RAF-NOACs studies, Paciaroni et al. found that older age, infarct size ≥1.5 cm and severe left atrial enlargement are significantly associated with long-term prognosis in patients suffering from NVAF-related AIS. Therefore, the Authors derived and validated the ALESSA score (Table 7) , which has a good predictive power in predicting stroke recurrence (area under the receiving operating characteristic curve 0.646 [95% confidence interval (CI): 0.529-0.763], while the power to predict hemorrhagic events is low (AUC 0.407, 95% CI: 0.275-0.540). 27 After DOACs marketing, the confidence in their use in patients with NVAF and venous thromboembolism together with their favorable pharmacological profile (rapid onset of action and lower risk of intracranial bleeding compared with VKAs) has led physicians to consider the use of DOACs in the early phase of NVAF-related AIS despite the absence of data in phase III RCTs. In a previous study performed in the Internal Medicine Ward of Santa Maria Nuova Hospital, Florence, Italy, Moroni et al. demonstrated that in the era of DOACs the percentage of patients with NVAF-related AIS who underwent anticoagulation before hospital discharge was 69.5% and this percentage increased from 62.5% in 2014 to 88% in 2016. 18 In this study, enclosed with the review by Masotti et al., 90-day stroke recurrence, intracranial bleeding and all-cause mortality were 1%, 0% and 3% respectively. In the study by Moroni et al. median mRS at hospital discharge and after 90-day in patients receiving DOACs was 3 (1-4) and 2 (1-3), respectively. In patients not receiving DOACs mRS at hospital discharge and after 90-day was 5 (4-5) and 5 (4-6), respectively. 90-day all-cause mortality in patients not receiving DOACs was 57.1%. Age, severe neurological sequelae and renal impairment were associated with failure to prescribe DOACs. 18 Similar results were found by Deguchi et al. who found that warfarin use at admission, higher mRS score and renal impairment were associated with failure to prescribe DOACs. 28 In the study by Moroni et al. it was observed that the delay in DOACs introduction was associated with infarct size. In fact, patients with small stroke received DOACs with a delay of 3.2±2.2 days, those with a medium stroke received DOACs after 5.2±3.3 days, and those with a large stroke received DOACs after 6.4±2.9 days. Moreover, the delay of DOACs starting was associated with NIHSS score. Patients with NIHSS scores <8 received DOACs with a delay of 4.1±3.1 days, those with NIHSS scores in the range 8-16 with a delay of 6.7±3.7 days, and the delay for patients with NIHSS scores >16 was 6.5±3.8 days 18 ). Similar results were found by Deguchi et al. 29 in the SAMURAI Study in which the delay of DOACs introduction was associated with severity of stroke and by Macha et al. who found that the delay in DOACs starting time was associated with infarct size and localization. 30 Of note 
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Macha et al. found that the delay of DOACs starting time progressively increased whether patients had TIA, non-extensive supratentorial infarct, infratentorial infarct or extensive supratentorial infarct, respectively. 30 More interestingly, in the RAF-NOACs study Paciaroni et al. found a 5.2% 90-day incidence of the composite endpoint TIA/stroke recurrence, systemic embolism and major intracranial and extracranial bleeding compared to 12.6% in the RAF study. The best temporal window associated with lower risk of the composite endpoint was between 3 and 14 days from stroke onset, while starting DOACs within 48 h or after 14 days was associated with a 12.4 and 9.1% 90-day incidence of the composite endpoint, respectively. 10, 19 Consequently, based on available literature evidence and recommendations, it could be speculated about the fact that patients with small supratentorial infarct size, mild stroke severity (NIHSS score <8) and low HT risk could start anticoagulation close to third-fourth day, while patients with large supratentorial infarct size or infratentorial infarct, serious stroke severity (NIHSS score >16) and high HT risk could start anticoagulation close to fourteenth day. Patients with medium infarct size, mild stroke severity (NIHSS 8-16) and low HT risk could start anticoagulation between 6 and 10 days from stroke onset. It should be remarked that in the RAF study, patients with high CHA 2 DS 2 -VASC score and moderate-severe left atrial enlargement were at higher risk of composite endpoint TIA/stroke recurrence and HT, whereas patients receiving bridging therapy with low molecular weight heparins were at higher risk of HT. Therefore, additional factors other than infarct size and NIHSS score should be taken into account when deciding about DOACs starting time. Table 8 summarizes variables favoring the choice to early starting (within one week) of DOACs in NVAFrelated AIS.
Conclusions
Anticoagulation represents the best choice for secondary prevention in patients suffering from NVAF-related AIS. The optimal timing for starting anticoagulation in this context remains unclear despite the RAF study showed that starting anticoagulation within the 4 to 14 days temporal window from stroke onset is associated with lower risk of stroke recurrence and/or HT. 10 Awaiting findings from ongoing prospective RCTs on DOACs introduced in the early phase of NVAF-related AIS, the real life evidence suggests that starting DOACs in this context seems safer and associated with lower stroke recurrence and all-cause mortality risk compared to traditional treatment. 
